Esperion Therapeutics, Inc. growth

Reported trailing growth, forward expectations and three-year compound growth rates.

Trailing growth

Year over year

Revenue: +61.1%
EBITDA: +145.1%
EBIT: +289.6%
EPS: +97.0%
Free cash flow: +81.9%
Operating cash flow: +81.8%

Forward estimates

Revenue: -49.8%
EBITDA: —
EPS: +361.7%

Three-year CAGR

Revenue: +74.8%
EBITDA: +743.8%
EBIT: +10.8%
Net income: +56.2%
EPS: +60.7%
Free cash flow: +45.4%

Latest available reported and market-derived figures. A dash means the source dataset does not currently cover that metric; it does not imply a zero value.